[go: up one dir, main page]

AU1653101A - Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders - Google Patents

Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders

Info

Publication number
AU1653101A
AU1653101A AU16531/01A AU1653101A AU1653101A AU 1653101 A AU1653101 A AU 1653101A AU 16531/01 A AU16531/01 A AU 16531/01A AU 1653101 A AU1653101 A AU 1653101A AU 1653101 A AU1653101 A AU 1653101A
Authority
AU
Australia
Prior art keywords
prevention
treatment
mediated disorders
kinase mediated
thiazole derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU16531/01A
Inventor
Magnus Ingelman-Sundberg
Anastasia Simi
Niclas Tindberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU1653101A publication Critical patent/AU1653101A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU16531/01A 1999-11-18 2000-11-15 Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders Abandoned AU1653101A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9904177A SE9904177D0 (en) 1999-11-18 1999-11-18 Novel compounds
SE9904177 1999-11-18
PCT/SE2000/002252 WO2001035959A1 (en) 1999-11-18 2000-11-15 Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders

Publications (1)

Publication Number Publication Date
AU1653101A true AU1653101A (en) 2001-05-30

Family

ID=20417767

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16531/01A Abandoned AU1653101A (en) 1999-11-18 2000-11-15 Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders

Country Status (3)

Country Link
AU (1) AU1653101A (en)
SE (1) SE9904177D0 (en)
WO (1) WO2001035959A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303538A2 (en) 2000-12-21 2005-02-28 Bristol-Myers Squibb Co. Thiazolyl inhibitors of tec family tyrosine kinases and pharmaceutical compositions containing them
JP2006516548A (en) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト Drug delivery from rapidly gelled polymer compositions
US7169771B2 (en) 2003-02-06 2007-01-30 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
WO2006021896A2 (en) * 2004-08-27 2006-03-02 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
US8063052B2 (en) * 2004-09-01 2011-11-22 Systagenix Wound Management (Us), Inc. Wound healing
WO2006109196A2 (en) * 2005-02-04 2006-10-19 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
ES2897740T3 (en) 2011-12-28 2022-03-02 Kyoto Prefectural Public Univ Corp Normalization of corneal endothelial cell culture
WO2015072580A1 (en) 2013-11-14 2015-05-21 学校法人同志社 Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8900564D0 (en) * 1989-02-17 1989-02-17 Astra Ab NOVEL MEDICINAL USE
SE9002659D0 (en) * 1990-08-15 1990-08-15 Astra Ab NEW PHARMACEUTICAL FORMULATIONS
SE9302333D0 (en) * 1993-07-06 1993-07-06 Ab Astra NEW COMPOUNDS
ZA944647B (en) * 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
JP4403482B2 (en) * 1997-12-22 2010-01-27 バイエル コーポレイション Intermediates for the synthesis of substituted heterocyclic ureas and methods for their preparation

Also Published As

Publication number Publication date
WO2001035959A1 (en) 2001-05-25
SE9904177D0 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
AU5309400A (en) Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives
AU2001247474A1 (en) Compounds for the treatment of psychiatric or substance abuse disorders
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
AU6462500A (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
AU6910600A (en) Methods for the treatment of mental disorders
IL145301A0 (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders
AU2002252227A1 (en) Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU4364400A (en) Azaindole derivatives for the treatment of depression
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU5042000A (en) Methods of treating proliferative disorders
AU4694999A (en) Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
AU5908300A (en) Prevention and treatment of amyloid-associated disorders
AU1356201A (en) Treatment of hyperproliferative disorders
AU1653101A (en) Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU5912900A (en) Quinuclidine derivatives for treatment of neurological disorders
AU7106300A (en) Treatment of skin disorders
AU2080201A (en) Treatment of addiction disorders
AU1028501A (en) Isoquinoline and quinazoline derivatives for the treatment of cns disorders
AU2002221566A1 (en) Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
AU5416500A (en) Pharmaceutical composition for the treatment of calcification
AU6007900A (en) Azetidine carboxamide derivatives for the treatment of cns disorders
AU2683500A (en) Compositions for the treatment of pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase